Context Therapeutics Reports Q3 2026 Results and CTIM-76 Progress

Context Therapeutics reported a 22% confirmed response rate in a Phase 1 CTIM-76 cohort and said its $34.4 million in cash is expected to fund operations into early Q4 2027.Key Highlights:Original SEC Filing: Context Therapeutics Inc. [ CNTX ] - 8-K - Nov. 10, 2026This is an AI-powered summary. It…